Emerade Adrenaline Autoinjectors recalled in UK
- PDF / 151,966 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 28 Downloads / 164 Views
1
Emerade Adrenaline Autoinjectors recalled in UK The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug alert ˇ advising that Pharmaswiss Ceska Republika, an affiliate of Bausch & Lomb UK, is recalling all unexpired batches of Emerade Adrenaline Autoinjectors (epinephrine pens), including 150, 300 and 500µg solutions for injection in pre-filled syringes. This follows identification of an error in a component of the autoinjectors which may result in their failure to activate and deliver epinephrine. Emerade pens currently held by patients are not being recalled; patients and caregivers should continue using them until their expiry date but should be informed of the risk of failure to activate. They should carry two pens at all times, and immediately use the second one if the first one fails to activate despite firm pressure. They should be advised not to expose Emerade pens to temperatures above 25°C because higher temperatures this may increase the risk of the fault. Healthcare professionals should stop supplying Emerade pens and return all remaining stock to the supplier. Until the error has been corrected, they should prescribe an alternative brand (EpiPen or Jext) and ensure that training in their use is provided. If a patient was previously supplied with Emerade 500µg pens, EpiPen or Jext in strengths of 300µ will be appropriate alternatives, says the MHRA. The MHRA and the UK Department of Health and Social Care are working to stabilise the supply of adrenaline pens in the UK. MHRA. Class 2 Medicines recall: Emerade 150, 300 and 500 microgram solution for injection in a pre-filled syringe (MDR 57-08/19). Internet Document : 29 Nov 2019. Available from: URL: https://www.gov.uk/drug-device-alerts/ class-2-medicines-recall-emerade-150-300-and-500-microgram-solution-for803440069 injection-in-a-pre-filled-syringe-mdr-57-08-19
0114-9954/19/1783-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Dec 2019 No. 1783
Data Loading...
